Company profile
Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Azetukalner | phase3 | — | 6 | active |
| EZOGABINE | phase3 | — | 13 | completed, terminated, withdrawn |
| FUNAPIDE | phase2 | — | 5 | no active trials |
| Zandatrigine | phase1 | — | 5 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01195636 | phase2 | completed | 2010-08-01 | 2011-03-01 | Xenon Pharmaceuticals Inc. | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) |
| NCT07172516 | phase3 | recruiting | 2025-08-08 | 2028-06-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
| NCT06775379 | phase3 | recruiting | 2024-12-20 | 2026-08-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
| NCT07076407 | phase3 | recruiting | 2025-07-08 | 2027-05-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) |
| NCT05614063 | phase3 | completed | 2022-11-18 | 2026-01-12 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
FDA applications (0)
No records yet.